In conjunction with this announcement, Roivant also disclosed topline results from Immunovant's two Phase 3 clinical studies evaluating batoclimab as a treatment for adults with active, moderate-to-severe thyroid eye disease (TED). Unfortunately, these studies did not meet their primary endpoint of achieving a responder rate of ≥2mm proptosis improvement at Week 24. However, safety results were consistent with previous findings, and no new safety signals were identified. The studies indicated that patients experienced greater proptosis improvement during the initial high-dose treatment phase compared to the subsequent low-dose phase, suggesting a potential benefit from deeper IgG suppression.
Roivant will host an investor call to discuss these updates further, emphasizing their commitment to advancing innovative therapies in areas of high unmet need. The company continues to focus on the rapid development of brepocitinib and other investigational treatments, aiming to improve patient outcomes in challenging conditions. The market response to these announcements will be closely monitored, as they may influence Roivant's stock performance in the near term.
